While COVID-19 permeates the lives of everyone, the Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS) Study has continued to work toward identifying and addressing the inequities and inefficiencies in the global insulin market.

Because the pandemic, and unintended consequences of actions to prevent the spread of COVID-19, continue to interrupt and disrupt the medicines supply chain, ACCISS has adopted a stronger emphasis and reflection on the impact of COVID-19 on access to insulin.

Letter to Dr Tedros: The Challenge of Access to Insulin Amidst COVID-19

ACCISS wrote to the Director-General of the World Health Organization (WHO) on the impact of COVID-19 on access to medicines for non-communicable diseases, particularly insulin, now and after the crisis ends.

Supported by a group of nine other organisations working to improve the health outcomes of people living with diabetes, the letter identifies four key challenges and gives recommendations to mitigate the problem.

Read the full letter.

ACCISS during COVID-19


Even in normal circumstances, access to insulin is poor in many countries. The COVID-19 crisis makes the situation far worse, with national health systems overwhelmed and people forced to deal with the consequences of home confinement. Co-Lead of the ACCISS study, Dr Marg Ewen, discussed the current situation internationally to illustrate the reality for people who need insulin.

Every project within Health Action International has had to adapt over the last few months. Learn about the ways in which each of our projects, and the organisation as a whole, have shifted and responded to the ongoing pandemic that continues to impact access to medicines for everyone, everywhere.

Responding to COVID-19